Takeda Faces Setback as Phase 3 Trial for Promising Lung Cancer Drug Exkivity Fails

Takeda Faces Setback as Phase 3 Trial for Promising Lung Cancer Drug Exkivity Fails

In a major blow to Takeda Pharmaceutical Company, the highly anticipated targeted non-small cell lung drug Exkivity has suffered a…